Pembrolizumab in a Patient with Treatment-Naive Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer.

ABSTRACT: Immune check point inhibitor (ICI) therapy can be a potentially effective salvage treatment for anaplastic thyroid cancer (ATC) with progression despite standard of care therapies. We report a case of unresectable treatment-naïve ATC showing a dramatic and durable response to first-line pembrolizumab therapy. A 69-year-old male presented with a large, right-sided neck mass associated with compressive symptoms. A neck ultrasound showed a large, right-sided, and highly suspicious thyroid nodule. A fine needle aspiration (FNA) biopsy revealed tumor cells consistent with ATC that were positive for PD-L1, with an expression score of >95% and negative for the BRAF V600E mutation. Imaging studies were negative for distant metastases. The disease was declared surgically inoperable, and the patient

SUBMITTER: Nabhan F 

PROVIDER: S-EPMC8166484 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature